首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1918125

多重檢測市場－2026-2031年預測

Multiplex Assay Market - Forecast from 2026 to 2031

出版日期: 2026年01月15日 | 出版商:

Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

多重檢測市場預計將從 2025 年的 1,607,267,000 美元成長到 2031 年的 3,806,265,000 美元，複合年成長率為 15.45%。

多重檢測市場正經歷顯著成長，這主要得益於技術進步、醫療保健模式的轉變以及對分析複雜性日益成長的需求。這些先進的科學技術能夠同時測量單一樣本中的多種分析物或標靶，已成為生物化學、分子生物學、醫學和診斷領域不可或缺的工具。生物技術產業的擴張、個人化醫療的引入以及慢性病盛行率的上升，都為市場發展注入了強勁動力。

主要市場促進因素

固有的技術優勢

多重檢測相比傳統的單重檢測具有顯著優勢，使其在科學研究、診斷和臨床應用中極具價值。其最顯著的優勢在於能夠同時分析單一樣本中的多種分析物，包括蛋白質、核酸和其他分子。這種能力能夠提供對生物過程、疾病路徑和藥物反應的全面而整體的洞察，而這是傳統的單重檢測無法實現或難以實現的。

此外，多重檢測透過同時檢測多種生物標記和疾病指標，提高了診斷準確性。這種多變量方法降低了假陽性和假陰性的機率，從而可能獲得更可靠的結果並改善患者預後。同時分析多個標靶的效率提升，意味著所需檢體量減少、試劑消耗降低、結果報告速度加快以及每個資料點的總體成本降低——所有這些因素在研究和臨床應用中都至關重要。

製藥和生物技術領域的擴張

不斷擴張的製藥業和分子診斷技術的進步是推動市場發展的催化劑。生物技術、基因組學和蛋白質組學的持續發展使得許多潛在生物標記和治療標靶得以被發現。多重檢測在同時評估藥物對多個標靶的潛在作用方面發揮關鍵作用，從而加快藥物研發進程並提高研究效率。生物技術產業正在快速發展，預計到2025年，印度生物技術Start-Ups將達到1萬家，這表明該行業在全球範圍內呈現成長態勢，並體現了對多重檢測等先進分析工具日益成長的需求。

融入個人化醫療

醫療產業向個人化醫療轉型需要對多種生物標記有全面的了解，這使得多重檢測成為一項至關重要的基礎技術。這些檢測能夠同時分析多種遺傳、蛋白質組和分子標記物，從而支持開發針對個別患者最佳化的個人化治療策略。新型經營模式的出現推動了個人化醫療的廣泛應用。例如，總部位於紐約的Start-UpsMalla 於 2023 年 5 月推出了其服務。該公司透過每月 65 美元的會員制模式提供功能性和個人化醫療服務，其中包括一對一的個人化健康計畫諮詢。

慢性病和人口壓力

多重檢測技術已被證明在慢性病研究和管理中極為有用，它能夠追蹤生物標記隨時間的變化，並深入了解疾病動態。慢性病盛行率的不斷上升是一個重要的成長要素，這些疾病每年導致4,100萬人死亡（佔全球所有死亡人數的74%）。多重檢測技術的分析能力使得全面監測和管理策略成為可能，而這些策略使用傳統方法則難以實現。

此外，人口老化也推動了多重檢測的需求，因為老年人通常患有多種合併症，例如心血管疾病和糖尿病，這些疾病需要複雜的診斷方法。人口結構變化顯著，預計2015年至2050年間，全球60歲及以上人口的比例將從12%增至22%，這將持續推動對高效多分析物診斷解決方案的需求。

市場限制

儘管多重檢測市場成長前景強勁，但仍面臨一些可能影響其擴張的挑戰。成本是限制阻礙因素之一，多重檢測的初始成本和持續成本仍然相對較高。這些成本包括儀器購買、試劑以及檢測設計和數據分析所需的專業知識。這些財務障礙可能會限制其應用，尤其是在資源受限的環境中，預算限制使得投資先進的分析平台變得困難。

此外，設計和最佳化多重檢測比傳統的單重檢測方法更複雜，因為必須仔細考慮交叉反應性、靈敏度和每個分析物的動態範圍等因素，這使得開發過程更加耗時且耗力。

區域和近期趨勢

預計在預測期內，北美將佔據顯著的市場佔有率，這主要得益於慢性病的高發生率、老年人口的成長、藥物研發投入的增加以及政府的支持。截至2020年，美國約有六分之一的人口年齡在65歲及以上，這推動了多重檢測的需求。

近期市場趨勢凸顯了持續創新的重要性。 2023年2月，Quansys Biosciences推出了一條用於非人靈長類動物模型的多重ELISA檢驗產品線，該產品線包含四種可客製化試劑盒。在技術進步、醫療保健轉型以及現代醫學和研究分析需求的推動下，多重檢測市場持續發展。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The multiplex assay market is experiencing significant growth driven by technological advancement, evolving healthcare paradigms, and increasing analytical complexity demands. These sophisticated scientific techniques, enabling simultaneous measurement of multiple analytes or targets within a single sample, have become indispensable tools across biochemistry, molecular biology, medicine, and diagnostics. The convergence of biotechnology sector expansion, personalized medicine adoption, and rising chronic disease prevalence is propelling market momentum.

Core Market Drivers

Intrinsic Technological Advantages

Multiplex assays offer compelling benefits compared to traditional singleplex tests, making them highly valuable across research, diagnostic, and clinical applications. The most significant advantage lies in their ability to analyze multiple analytes-including proteins, nucleic acids, or other molecules-simultaneously within a single sample. This capability provides comprehensive, holistic views of biological processes, disease pathways, and drug responses that would be impossible or impractical to achieve through sequential singleplex testing.

Furthermore, multiplex assays enhance diagnostic accuracy by considering multiple biomarkers or disease indicators concurrently. This multi-parameter approach reduces the likelihood of false positives or negatives, yielding more reliable results and improved patient outcomes. The efficiency gains from analyzing numerous targets simultaneously translate to reduced sample volumes, decreased reagent consumption, faster turnaround times, and lower overall costs per data point-critical considerations in both research and clinical settings.

Pharmaceutical and Biotechnology Expansion

The expanding pharmaceutical sector and advances in molecular diagnostics are substantial market catalysts. Continuous progress in biotechnology, genomics, and proteomics has enabled identification of numerous potential biomarkers and therapeutic targets. Multiplex assays play crucial roles in assessing potential drug effects on multiple targets simultaneously, accelerating drug development timelines and improving research efficiency. The biotechnology landscape is expanding rapidly, with India's biotech startup ecosystem expected to reach 10,000 companies by 2025, demonstrating the sector's global growth trajectory and associated demand for sophisticated analytical tools like multiplex assays.

Personalized Medicine Integration

The healthcare industry's shift toward personalized medicine requires comprehensive understanding of multiple biomarkers, positioning multiplex assays as essential enabling technologies. These assays facilitate simultaneous analysis of diverse genetic, proteomic, and molecular markers, supporting development of tailored treatment strategies optimized for individual patient profiles. The growing adoption of personalized medicine is evidenced by emerging business models-exemplified by the May 2023 launch of Malla, a New York-based startup offering functional and personalized medicine through accessible membership models at $65 monthly, including one-to-one consultations for personalized health planning.

Chronic Disease and Demographic Pressures

Multiplex assays have proven invaluable in studying and managing chronic diseases, offering capabilities to track biomarker changes over time and providing insights into disease dynamics. The rising chronic disease prevalence represents a significant growth driver, with these conditions accounting for 41 million deaths annually-74% of all deaths worldwide. The analytical power of multiplex assays enables comprehensive disease monitoring and management strategies that would be impractical using conventional methods.

Additionally, the growing geriatric population accelerates multiplex assay demand, as elderly individuals commonly present with multiple concurrent conditions including cardiovascular disease and diabetes, requiring complex diagnostic approaches. The demographic shift is substantial: the proportion of people aged over 60 years worldwide is projected to increase from 12% to 22% between 2015 and 2050, creating sustained demand for efficient multi-parameter diagnostic solutions.

Market Constraints

Despite robust growth prospects, the multiplex assay market faces challenges that may impact expansion. Cost represents a significant limiting factor, with initial setup expenses and ongoing costs associated with multiplex assays remaining relatively high. This includes equipment acquisition, reagents, and specialized expertise requirements for assay design and data analysis. These financial barriers may limit adoption, particularly in resource-constrained settings where budget limitations preclude investment in advanced analytical platforms.

Additionally, designing and optimizing multiplex assays involves greater complexity than traditional singleplex approaches. Development requires careful consideration of factors including cross-reactivity, sensitivity, and dynamic range for each analyte, making the process time-consuming and resource-intensive.

Regional Dynamics and Recent Developments

North America is positioned to hold significant market share during the forecast period, supported by higher chronic disease prevalence, growing geriatric populations, increasing R&D spending on drug development, and government support. Approximately one in six people in the U.S. were aged 65 years or above in 2020, accelerating multiplex assay demand.

Recent market developments underscore ongoing innovation. In February 2023, Quansys Biosciences launched a non-human primate model line of multiplex ELISA assays comprising four customizable kits. The multiplex assay market continues evolving, driven by technological sophistication, healthcare transformation, and analytical demands of modern medicine and research.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Multiplex Assay Market Segmentation

By Type
Protein Multiplex Assays
Nucleic Acid Multiplex Assays
Cell-based Multiples Assays
By Product
Consumables
Instruments
Software
By Technology
Flow Cytometry
Fluorescence Detection
Luminescence
Multiplex Real-time PCR
Other Technologies
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MULTIPLEX ASSAY MARKET BY TYPE

5.1. Introduction
5.2. Protein Multiplex Assays
5.3. Nucleic Acid Multiplex Assays
5.4. Cell-based Multiples Assays

6. MULTIPLEX ASSAY MARKET BY PRODUCT

6.1. Introduction
6.2. Consumables
6.3. Instruments
6.4. Software

7. MULTIPLEX ASSAY MARKET BY TECHNOLOGY

7.1. Introduction
7.2. Flow Cytometry
7.3. Fluorescence Detection
7.4. Luminescence
7.5. Multiplex Real-time PCR
7.6. Other Technologies

8. MULTIPLEX ASSAY MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others